You’ve seen GEN’s list of biosimilars to watch; now, following is a list of 15 vaccines, ranked by sales and representing the 15 top-selling vaccines of 2012. Sales figures come mostly from data disclosed by vaccine developers, except where otherwise noted. Vaccines are listed by their name, their proper name as filed with FDA or furnished by vaccine developers, sales figures for 2012 and 2011, the percentage of year-over-year sales growth, the name of the vaccine developer/sponsor, and indications. The source for indications is FDA’s list of Vaccines Licensed for Immunization and Distribution in the U.S. with Supporting Documents, available online on the agency’s website.
The list reveals, first off, how relatively few drug/vaccine developers are responsible for the top sellers. Merck & Co. and Sanofi account for more than half of the vaccines on the list, both individually and collectively; the two companies maintain a joint venture, Sanofi Pasteur MSD, which discloses sales results for only two of its vaccines. Other solid performers in vaccines include GlaxoSmithKline, which placed five vaccines on the list, and Pfizer, whose vaccine Prevnar 13 topped the list with nearly $4 billion in sales last year.
Another pharma giant, Novartis, can be expected to show up on next year’s list given talk earlier this year that it planned in 2013 to launch the meningitis vaccine Bexsero, a Meningococcal Group B Vaccine [rDNA, component, adsorbed] for use against meningococcal serogroup B (MenB); and Flucelvax, the first cell-culture derived influenza vaccine approved in the U.S., designed to protect adults 18 years and older against seasonal flu. The latter is expected to be launched in time for the 2013–2014 flu season. Manufacturing ramp-ups to both launches account for Novartis’ vaccines and diagnostics division finishing last year with a $250 million loss on $1.9 billion in sales.